Download

Antibody Identification






Advertisement
/ 60 []
Download Presentation
Comments
gabi
From:
|  
(1124) |   (0) |   (0)
Views: 527 | Added:
Rate Presentation: 1 0
Description:
Antibody Identification. Mohammed Jaber. Antibody Presence . Presence of an antibody may be indicated by the following serological tests: A discrepancy in the results of cell and serum ABH grouping. A positive test for unexpected antibodies. A positive direct Coomb’s test.
Antibody Identification

An Image/Link below is provided (as is) to

Download Policy: Content on the Website is provided to you AS IS for your information and personal use only and may not be sold or licensed nor shared on other sites. SlideServe reserves the right to change this policy at anytime. While downloading, If for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.











- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -




Slide 1

Antibody Identification

Mohammed Jaber

Slide 2

Antibody Presence

Presence of an antibody may be indicated by the following serological tests:

A discrepancy in the results of cell and serum ABH grouping.

A positive test for unexpected antibodies.

A positive direct Coomb’s test.

An incompatible major cross match.

Slide 3

The Basics…..

  • As we said in the previous lecture,

    • Antibody Screens use 2 or 3 Screening Cells to “detect” if antibodies are present in the serum

    • If antibodies are detected, then they should be identified…

present

Not present

Slide 4

Why do we need to identify?

  • Antibody identification is an important component of compatibility testing

  • It will identify any unexpected antibodies in the patient’s serum

  • If a person with an antibody is exposed to donor cells with the corresponding antigen, serious side effects can occur (i.e. transfusion reactions).

Slide 5

Key Concepts

  • In blood banking, we test “knowns” with “unknowns”:-

  • When detecting/screening and/or identifying antibodies, we test patient serum (unknown that contain blood bank antibodies) with reagent RBCs (known)

Known: Unknown:

Reagent RBCs + patient serum

Reagent antisera + patient RBCs

Slide 6

Reagent RBCs

  • Screening Red Cells and Panel Red Cells are the same with minor differences:

    • Screening red cells

      • Antibody detection/screening

      • Sets of only 2 or 3 vials

    • Panel red cells

      • Antibody identification

      • At least 10 vials/set

Slide 7

Antibody Panel vs. Screen

  • An antibody panel is just an extended version of an antibody screen

  • The screen only uses 2-3 red cells:

Slide 8

Antibody Panel

  • While antibody panel usually includes at least 10 panel cells: (8-16 group O RBCs)

Slide 9

Panel Red Cells

  • Group O red blood cells obtained from donors

Slide 10

Panel Red Cells

  • Each of the panel cells has been antigen typed (shown on antigram)

    • + refers to the presence of the antigen

    • 0 refers to the absence of the antigen

Example: Panel Cell #10 has 9 antigens present: c, e, f, M, s, Leb, k, Fya, and Jka

Slide 11

Panel Red Cells

  • An autocontrol (AC) should also be run with ALL panels

Autocontrol

Patient RBCs + Patient serum

Slide 12

Panel Red Cells

  • The same phases used in an antibody screen are used in a panel

  • IS

  • 37°C

  • AHG

Slide 13

1

2

3

4

5

6

7

8

9

10

11

Antibody ID Testing

  • A tube is labeled for each of the panel cells plus one tube for AC:





AC

1 drop of each panel cell

+

2 drops of the patients serum

Do not forget to write patient name and ID, Lab No.

Patient cells



Patient serum

Slide 14

IS Phase

  • Perform immediate spin (IS) and grade agglutination; inspect for hemolysis

  • Record the results in the appropriate space as shown:

2+

0

0

Up to the Last tube

Slide 15

(LISS) 37°C Phase

  • 2 drops of LISS are added, mixed and the mixture is incubated for 10-15 minutes

  • Centrifuge and check for agglutination

  • Record results as previous but now fill the 37°C lane.

Slide 16

Agglutination Viewer

Slide 18

(LISS) 37°C Phase

2+

0

0

0

0

0

2+

0

0

2+

0

2+

0

0

Slide 19

IAT Phase (or AHG)

  • Indirect Antiglobulin Test (IAT) – we’re testing whether or not possible antibodies in patient’s serum will react with RBCs in vitro

  • To do this we use the Anti-Human Globulin reagent (AHG)

    • Polyspecific AHG

    • Monospecific Anti-IgG

    • Monospecific Anti-Complement

Slide 20

IAT (AHG) Phase

  • Wash red cells 3X with saline (manual or automated (cell washer))

  • Add 2 drops of AHG and gently mix

    • Centrifuge

    • Read for agglutination

    • Record reactions

Slide 21

IAT (AHG) Phase

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

0

0

0

Slide 22

And don’t forget….

….add “check” cells to any negative AHG !

Slide 23

All cells are negative at AHG, so add “Check” Cells

Slide 24

You have agglutination…now what?

CC

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

0

??

Slide 25

Interpreting Antibody Panels

  • There are a few basic steps to follow when interpreting panels

    • “Ruling out” means crossing out antigens that did not react

    • Circle the antigens that are not crossed out

    • Consider antibody’s (from the circled) usual reactivity

    • Look for a matching pattern

Slide 26

Always remember:

An antibody will only react with cells that have the corresponding antigen; antibodies will not react with cells that do not have the antigen

Slide 27

Here’s an example:

Slide 28

1. Ruling Out

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

0

0

0

Cross out antigens that show NO REACTION in any phase; do NOTcross out heterozygous antigens that show dosage.

Slide 29

2. Circle antigens not crossed out

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

0

0

0

Slide 30

3. Consider antibody’s usual reactivity

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

0

0

0

Lea is normally a Cold-Reacting antibody (IgM), so it makes sense that we see the reaction in the IS phase of testing; The E antigen will usually react at warmer temperatures

Slide 31

4. Look for a matching pattern

E doesn’t match and it’s a warmer rxn Ab

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

2+

0

0

0

0

0

0

0

0

0

0

0

…Yes, there is a matching pattern!

Slide 32

Interpretation:

anti-Lea

Slide 33

Guidelines

  • Again, it’s important to look at:

    • Autocontrol

      • Negative - alloantibody

      • Positive – autoantibody or DTR (i.e. alloantibodies)

    • Phases

      • IS – cold (IgM)

      • 37° - cold (some have higher thermal range) or warm reacting

      • AHG – warm (IgG)…significant!!

    • Reaction strength

      • 1 consistent strength – one antibody

      • Different strengths – multiple antibodies or dosage

Slide 34

About reaction strengths……

  • Strength of reaction may be due to “dosage”

    • If panel cells are homozygous, a strong reaction may be seen

    • If panel cells are heterozygous, reaction may be weak or even non-reactive

  • Panel cells that are heterozygous for an antigen should not be crossed out because antibody may be too weak to react (see previous example)

Slide 35

Guidelines (continued)

  • Matching the pattern

    • Single antibodies usually shows a pattern that matches one of the antigens (see previous panel example)

    • Multiple antibodies are more difficult to match because they often show mixed reaction strengths

Slide 36

Rule of three

  • The rule of three must be met to confirm the presence of the antibody

  • A p-value ≤ 0.05 must be observed

  • This gives a 95% confidence interval

  • How is it demonstrated?

    • Patient serum MUST be:

      • Positive with 3 panel cells with the antigen, +ve reaction.

      • Negative with 3 cells without the antigen and should not be reacting.

Slide 37

Our previous example fulfills the “rule of three”

2+

0

0

0

0

0

3 Positive cells

0

0

0

2+

0

0

0

0

0

0

0

0

2+

0

0

0

0

0

3 Negative cells

2+

0

0

0

0

0

0

0

0

0

0

0

Panel Cells 1, 4, and 7 are positive for the antigen and gave a reaction at IS

Panel Cells 8, 10, and 11 are negative for the antigen and did not give a reaction at IS

Slide 38

What if the “rule of three” is not fulfilled?

  • If there are not enough cells in the panel to fulfill the rule, then additional cells from another panel could be used

  • Most good (I do not know if we are good or not!!) labs carry different lot numbers of panel cells

Slide 39

Patient Antigen Typing (Phenotyping)

  • In addition to the rule of three, antigen typing the patient red cells can also confirm an antibody

  • How is this done?

    • Only perform this if the patient has NOT been recently transfused (donor cells could react (chimera)).

    • If reagent antisera (of the suspected antibody) is added to the patient RBCs, a negative reaction should result…Why?

Slide 40

Remember Landsteiner’s Rule

Individuals DO NOT make allo-antibodies against antigens they have

Slide 41

Multiple antibodies

  • Multiple antibodies may be more of a challenge than a single antibody

  • Why?

    • Reaction strengths can vary

    • Matching the pattern is difficult

Slide 42

So what we have to do?

  • Several procedures can be performed to identify multiple antibodies

    • Selected Cells

    • Neutralization

    • Chemical treatment

      • Proteolytic enzymes

      • Sulfhydryl reagents

      • ZZAP

Slide 43

1- Selected Red Cells

  • Selected cells are chosen from other panel or screening cells to confirm or eliminate the antibody.

  • The cells are “selected” from other panels because of their characteristics.

  • The number of selected cells needed depends on how may antibodies are identified.

Slide 44

Selected Red Cells ….. Cont’d

  • Every cell should be positive only for each of the antibodies and negative for the remaining suspicious antibodies

  • For example:

    • Let’s say you ran a panel and identified 3 different antibodies (you cannot rule out): anti-S, anti-Jka, and anti-P1

    • Selected cells could help…

Slide 45

Selected Red Cells ….. Cont’d

Ag they have

Reaction pattern

These results show that instead of 3 antibodies, there are actually 2: anti-S and anti-Jka

Slide 46

2- Neutralization

  • Some antibodies may be neutralized as a way of confirmation

  • Commercial “substances” bind to the antibodies in the patient serum, causing them to show no reaction when tested with the corresponding antigen (in panel)

Slide 47

Neutralization ….. Cont’d

  • Manufacturer’s directions should be followed and a positive dilutional control should always be used

    • The positive dilutional control contains saline and serum (no substance is added) and should remain positive with panel cells.

    • A control shows that a loss of reactivity is due to the neutralization and not to the dilution of the antibody strength when the substance is added

Slide 48

Neutralization ….. Cont’d

  • Common substances

    • P1 substance (derived from hydatid cyst fluid)

    • Lea and Lebsubstance (soluble antigen found in plasma and saliva)

    • Isubstance can be found in breast milk

      **you should be aware that many of these substances neutralize COLD antibodies; Cold antibodies can sometimes mask more clinically significant antibodies (IgG), an important reason to use neutralization techniques

Slide 49

3- Again: Proteolytic Enzymes

  • Can be used to enhance or destroy certain blood group antigens

  • Several enzymes exist:

    • Ficin (figs)

    • Bromelin (pineapple)

    • Papain (papaya)

  • In addition, enzyme procedures may be

    • One-step

    • Two-step

Slide 50

Enzymes

  • Enzymes remove the sialic acid from the RBC membrane, thus “destroying” it and allowing other antigens to be “enhanced”

  • Antigens destroyed: M, N, S, s, Duffy

  • Antigens enhanced: Rh, Kidd, Lewis, I, and P

Slide 51

Enzyme techniques

  • One-stage

    • Enzyme is added directly to the serum/panel cell mixture

  • Two-stage

    • Panel cells are pre-treated with an enzyme, and washed

    • Patient serum is added to treated panel cells and tested

Slide 52

Enzyme techniques

  • If there is no agglutination after treatment, then it is assumed the enzymes destroyed the antigen

Slide 53

Enzyme treatment

Enzyme treatment

Anti-K

Perfect match for anti-Fya

  • Duffy antigens destroyed

  • Kell antigens not affected

Slide 54

Summary

  • If an unexpected antibody is detected in a patient’s serum or plasma it must be identified.

  • Once identified the clinical significance must be determined.

Slide 55

Summary

  • If the antibody is clinically significant antigen negative donors must be found and crossmatched for the patient, a Coomb’s crossmatch must be done.

  • If the antibody is not clinically significantit is not necessary to provide antigen negative blood, but the donors must be compatible by the Coomb’s crossmatch.

Slide 56

Providing Compatible Donor Units

  • Once an antibody has been identified, the next task is to provide appropriate units of RBCs for transfusion.

  • When clinically insignificant antibodies are detected, use of crossmatch-compatible RBCs is appropriate.

Slide 57

Providing Compatible Donor Units

  • No further testing is needed to confirm compatibility when the antibody is anti-M, anti-N, anti-Pi. Lea, or Leb.

  • However, when a clinically significant antibody is identified, the blood must be cross-match compatible and confirmed as antigen-negative with reagent antisera.

Slide 58

Example

  • Knowledge of the incidence of antigens is useful for determining how many units of blood to screen or cross­match for patients with antibodies.

  • If a patient with an anti-Jk(a-) needed 4 units of blood, how many units would need to be tested to find them?

    Jk (a+)= 0.77

    Jk (a-) = 0.23

  • 4 units Jk(a-) blood needed = 17.4 units 0.23 incidence of Jk(a-)

  • In this case, testing 17 or 18 random units should yield 4 Jk(a-) units.

Slide 59

Example 2

  • The same calculations can be used when multiple antibodies are present if the antigen frequencies are first multiplied together.

  • E.g. a patient with an anti-K and anti-Jka, 10 random units would need to be tested to find 2 that are compatible.

    Jk(a+) = 0.77 K positive = 0.09

    Jk(a-) = 0.23 K negative = 0.91

  • Jk(a-) (0.23) X K negative (0.91) = 0.20 Jk(a-) and K negative

  • 2 units needed = 10 units 0.20 Jk(a-) and Kell negative

Slide 60

THE END!!


Copyright © 2014 SlideServe. All rights reserved | Powered By DigitalOfficePro